Psoriatic Arthritis | Treatment Algorithms: Claims Data Analysis | US | 2023

Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S. market for conventional DMARD-refractory PsA is crowded with multiple efficacious therapies, including six tumor necrosis factor-alpha (TNF-α) inhibitors, two interleukin (IL)-17 inhibitors, an IL-12/23 inhibitor, an IL-23 inhibitor, and two targeted oral agents (a PDE4 inhibitor and a JAK inhibitor). Additionally, the FDA approvals of another oral JAK inhibitor, Rinvoq (AbbVie), and a second-in-class IL-23 inhibitor, Skyrizi (AbbVie), have expanded physicians’ treatment armamentarium for PsA and increased competition among targeted therapies in this already cluttered market.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PsA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PsA patients?
• How have Skyrizi and Rinvoq been integrated into the treatment algorithm, and what is their source of business?
• What percentage of PsA patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
• What percentage of PsA patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: AbbVie, Amgen, Janssen, Novartis, Eli Lilly, Pfizer, Sun Pharma, UCB

Key drugs: Humira, Enbrel, Remicade, biosimilar infliximab, Cimzia, Simponi, Simponi Aria, Stelara, Cosentyx, Taltz, Tremfya, Skyrizi, Orencia, Otezla, Xeljanz, Rinvoq, methotrexate

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.